Fremanezumab Managed Access Program for Pediatric Patients

This is a Managed Access Program (MAP) based on a licensed physician's unsolicited request on a compassionate basis. Specifically, this MAP is for male and female pediatric patients 6 to 17 years with a diagnosis of either episodic or chronic migraine who have successfully completed the Teva sponsored study TV48125-CNS-30084 (SPACE study).

Inclusion Criteria: * Eligible patients may enter this CUP after successfully completing TV48125-CNS-30084 and all End of Study procedures * In the opinion of your physician/investigator are able to continue IMP (fremanezumab) in a safe and compliant way. Exclusion Criteria: * Additional criteria may apply, please contact your physician/investigator for more information.